Adaptive is pioneering the use of immunosequencing to revolutionize patient care. They translate the scale and precision of the adaptive immune system into products to diagnose and treat disease.
Adaptive Biotechnologies is engaged in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
The company offers immunosequencing platform to laboratories around the world to drive research in cancer and other immune-mediated diseases. It also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
TOTAL FUNDING 2017: $411,400,000.00
- May, 2015 / $195,000,000
- Jan, 2015 / $94,000,000
- April, 2014 / $100,000,000
- April, 2014 / $5,000,000
- Sept, 2013 / $2,500,000
- June, 2011 / $5,800,000
- May, 2010 / $4,500,000
- March, 2010 / $4,600,000
It was at Fred Hutchinson Cancer Research Center in Seattle, where Dr. Harlan Robins, Dr. Chris Carlson and Dr. Edus Warren were collaborating on a research project.
Over lunch one day, they started asking questions related to isolating and amplifying T-cell receptors from the human genome when they had an “aha!” moment.
Shortly after, in 2009, Adaptive Biotechnologies was born. The brain-child of two brothers (Chad and Harlan Robins) with one mission – to change the course of medicine and improve patient care worldwide. Over the years Adaptive has successfully gained the interest of strong investors, academic organizations and customers who understand the importance of sequencing the immune system in order to revolutionize the way we discover, diagnose and treat diseases.
To further the momentum, in 2015, Adaptive acquired Sequenta, Inc., a South San Francisco-based company dedicated to improving patient care in diseases mediated by immune cells through the discovery and development of novel clinical diagnostics. The company also launched its therapeutic effort to become a leading TCR discovery company to enable TCR-based cellular therapy development.
In 2018, Adaptive announced a partnership with Microsoft Research’s Healthcare NexT initiative to combine high-throughput immunosequencing and expert bioinformatics with machine learning and artificial intelligence, to map the entire human immune system and change the way diseases are diagnosed. By combining Adaptive’s powerful immune sequencing technologies with Microsoft’s research and large-scale machine learning and cloud computing capabilities, the partners aim to create individual disease diagnostics and ultimately a universal diagnostic – all from a simple blood test.
Now with over 200 employees, three locations, and products and services in both the research and diagnostics segments, Adaptive is not just a pioneer but also a leader in immunosequencing that will change the course of medicine worldwide.